logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hani M. Babiker

mayo clinic in florida
H指数:23
被引数:3,856

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

II期研究： futibatinib联合pembrolizumab治疗FGF19表达型晚期肝细胞癌患者的疗效观察

Oncologist
IF4.2
2026-08-250
OAAI
Nguyen H Tran; Mathias E Palmer; Angela Ulrich; Shaylene A McCue; Amit Mahipal; Wen Wee Ma; Hani M Babiker; Umair Majeed; Thorvardur R Halfdanarson; Robert R McWilliams; Zhaohui Jin; Ryan Carr; Lionel Aurelien Kankeu Fonkoua; Leslie Washburn; Caitlin Conboy; Rondell P Graham; Michael Torbenson; Patrick Starlinger; Krishan R Jethwa; Christopher Hallemeier; Alexander Revzin; Scott M Thompson; Ajit H Goenka; Sudhakar K Venkatesh; Mohamad B Sonbol; Mitesh J Borad; Tanios Bekaii-Saab; Gregory J Gores; Lewis R Roberts; Julie K Heimbach; Fang-Shu Ou
Intraperitoneal Chemotherapy Strategies in Pancreatic Ductal Adenocarcinoma: A Systematic Review of Hyperthermic Intraperitoneal Chemotherapy, Normothermic Intraperitoneal Chemotherapy, and Pressurized Intraperitoneal Aerosol Chemotherapy

胰腺导管腺癌的腹腔化疗策略：对温热腹腔化疗、常温腹腔化疗和加压腹腔气溶胶化疗的系统综述

Cancers
IF4.4
2026-01-060
OAAI
Nency Ganatra; Ahmed Abdelhakeem; Pragya Jain; Saivaishnavi Kamatham; Dina Elantably; Oluwatayo Adeoye; Hani M. Babiker; Conor D. O’Donnell; Umair Majeed
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study

一线阿替利珠单抗/贝伐珠单抗或度伐利尤单抗/特瑞普利单抗在晚期肝细胞癌中的应用：一项真实世界、多中心回顾性研究

ONCOLOGIST
IF4.2
2025-11-010
PRE
Kournoutas, Ioannis; Marell, Paulina; Gile, Jennifer; Peersen, Anina; Shah, Priyanshi; Vandommelen, Kyle; Kamath, Suneel D.; Gupta, Garima; Akce, Mehmet; Yang, Ju Dong; Chen, Pin-Jung; Naleid, Nikolas; Mahipal, Amit; Peterson, Nicole; Sahai, Vaibhav; Wee Ma, Wen; Jin, Zhaohui; Halfdanarson, Thorvardur; Fonkoua Kankeu, Lionel; Washburn, Leslie A.; Conboy, Caitlin B.; Torbenson, Michael; Goenka, Ajit; Thompson, Scott; Venkatesh, Sudhakar K.; Starlinger, Patrick; Roberts, Lewis; Gores, Gregory J.; Babiker, Hani; Ahn, Daniel; Borad, Mitesh; Bekaii-Saab, Tanios; Jatoi, Aminah; Mcwilliams, Robert R.; Ou, Fang-Shu; Tran, Nguyen H.
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
COMMUNICATIONS MEDICINE
IF6.3
2024-12-020
OAAI
Barnett, Reagan M.; Jang, Albert; Lanka, Sree; Fu, Pingfu; Bucheit, Leslie A.; Babiker, Hani; Bryce, Alan; Meyer, Haley M.; Choi, Yujin; Moore, Casey; Garje, Rohan; Gao, Xin; Kim, Dae Won; Chang, Richard Y.; Gulhati, Pat; Ramaker, Ryne; Bansal, Rani; Zhang, Tian; Oliver Sartor, A.; Armstrong, Andrew J.; Bilen, Mehmet A.; Barata, Pedro
Phase 1 trial of MEK1 inhibitor E6201 plus dabrafenib in patients (pts) with BRAF V600-mutated metastatic melanoma (MM) with central nervous system (CNS) metastases (mets)
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Seetharam, Mahesh; Dronca, Roxana; Dudek, Arkadiusz Z.; Nelson, Garth; Block, Matthew; Starling, Skylar; Baskin, Amber; Bradshaw, Renee; Nelson, Courtney; Andrews, Kylee; Birgin, Alisha; Watson, Cristina; Yan, Yiyi; Mahadevan, Daruka; Markovic, Svetomir; Myers, Tom; Paradiso, Linda; Babiker, Hani
Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Schram, Alison M.; Subbiah, Vivek; Liao, Chih-Yi (Andy); Moreno, Victor; Desamparados, Roda; Ponz-Sarvise, Mariano; Dotan, Efrat; Cassier, Philippe Alexandre; Moreno, Irene; Varkaris, Andreas; Kim, Richard D.; Garralda, Elena; Opdam, Frans; Tai, David; Italiano, Antoine; Oh, Do-Youn; Goyal, Lipika; Fontana, Elise; Liu, Jia; Boukovala, Myrto; Ghiringelli, Francois; Borad, Mitesh J.; Babiker, Hani; Jin, Zhaohui; Millward, Michael; Yachnin, Jeffrey; Kamath, Suneel Deepak; Coward, Jermaine M.; Yoo, Changhoon; Kelley, Robin Kate; Sahai, Vaibhav; Bridgewater, John; Springfield, Christoph; Florou, Vaia; El-Khoueiry, Anthony; Eskens, Ferry; Lin, Bruce; Paulson, Scott; Curigliano, Giuseppe; Murphy, Meredith; Deary, Alicia; Ricard, Fabien; Jen, Kai Yu; Ramirez, Florence (Tianhui); Blakesley, Rick E.; Schmidt-Kittler, Oleg; Mar, Brenton G.; Park, Joon Oh; Hollebecque, Antoine
A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Alistar, A.; Mahalingam, D.; Barve, M.; Borad, M.; Babiker, H.; Xie, H.; Choi, B.; Ahn, J.; Choi, J.; Ahn, K.; Ryu, S.; Kim, J.; Yu, D.; Lee, S-J.; Jeon, B.; Proniuk, S.; Kim, J.; Nam, K.; El-Khoueiry, A. B.
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2023-03-227
OAAI
Autio, Karen A.; Higano, Celestia S.; Nordquist, Luke; Appleman, Leonard J.; Zhang, Tian; Zhu, Xin-Hua; Babiker, Hani; Vogelzang, Nicholas J.; Prasad, Sandip M.; Schweizer, Michael T.; Madan, Ravi A.; Billotte, Stephane; Cavazos, Nora; Bogg, Orlaith; Li, Ray; Chan, Kam; Cho, Helen; Kaneda, Megan; Wang, I-Ming; Zheng, Jenny; Tang, Szu-Yu; Hollingsworth, Robert; Kern, Kenneth A.; Petrylak, Daniel P.

研究方向

暂未获取到该数据
M
Mitesh J. Borad
H 指数:82论文数:761被引数:5.9万
D
Daruka Mahadevan
H 指数:42论文数:245被引数:7,819
S
Sreenivasa R Chandana
H 指数:22论文数:149被引数:2,926
A
Ali McBride
H 指数:32论文数:395被引数:3,881
O
Oliver Sartor
H 指数:95论文数:1,252被引数:4.5万
D
Daniel H. Ahn
H 指数:38论文数:293被引数:6,216
T
Tanios Bekaii‐Saab
H 指数:82论文数:1,167被引数:2.7万
Z
Zhaohui Jin
H 指数:30论文数:243被引数:4,489
U
Umair Majeed
H 指数:10论文数:67被引数:744
V
Vivek Subbiah
H 指数:78论文数:1,440被引数:3.1万